(Q52907578)

9 May 2018

title

An evaluation of a measure of the proportion of the treatment effect explained by a surrogate marker. (English)

1 reference

9 May 2018

author name string

Bycott PW

series ordinal

1

1 reference

9 May 2018

Taylor JM

series ordinal

2

1 reference

9 May 2018

language of work or name

English

0 references

publication date

1 December 1998

1 reference

9 May 2018

Contemporary Clinical Trials

published in

1 reference

9 May 2018

volume

19

1 reference

9 May 2018

issue

6

1 reference

9 May 2018

page(s)

555-568

1 reference

9 May 2018

Surrogate end points in clinical trials: are we being misled?

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2898%2900039-7

7 January 2021

Surrogate endpoints in clinical trials: definition and operational criteria

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2898%2900039-7

7 January 2021

Statistical validation of intermediate endpoints for chronic diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2898%2900039-7

7 January 2021

Evaluating the role of CD4-lymphocyte counts as surrogate endpoints in human immunodeficiency virus clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2898%2900039-7

7 January 2021

Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2898%2900039-7

7 January 2021

Viral load and response to treatment of HIV

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2898%2900039-7

7 January 2021

Estimating the proportion of treatment effect explained by a surrogate marker.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2898%2900039-7

7 January 2021

Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2898%2900039-7

7 January 2021

Covariance analysis of censored survival data

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2898%2900039-7

7 January 2021

A comparison of smoothing techniques for CD4 data measured with error in a time-dependent Cox proportional hazards model

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2898%2900039-7

7 January 2021

Models for empirical Bayes estimators of longitudinal CD4 counts.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2898%2900039-7

7 January 2021

Meta-analysis for the evaluation of potential surrogate markers.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2898%2900039-7

7 January 2021

10.1016/S0197-2456(98)00039-7

Identifiers

DOI

1 reference

9 May 2018

1 reference

9 May 2018